Hostname: page-component-74656f9884-j7cmm Total loading time: 0 Render date: 2026-11-07T09:45:17.233Z Has data issue: false hasContentIssue false

Leishmania donovani: proteasome-mediated down-regulation of methionine adenosyltransferase

Published online by Cambridge University Press:  03 August 2011

YOLANDA PÉREZ-PERTEJO*
Affiliation:
Departamento de Farmacología y Toxicología (INTOXCAL), Universidad de León, Campus de Vegazana s/n; 24071 León, Spain
RAQUEL ÁLVAREZ-VELILLA
Affiliation:
Departamento de Farmacología y Toxicología (INTOXCAL), Universidad de León, Campus de Vegazana s/n; 24071 León, Spain
CARLOS GARCÍA ESTRADA
Affiliation:
Departamento de Farmacología y Toxicología (INTOXCAL), Universidad de León, Campus de Vegazana s/n; 24071 León, Spain
RAFAEL BALAÑA-FOUCE
Affiliation:
Departamento de Farmacología y Toxicología (INTOXCAL), Universidad de León, Campus de Vegazana s/n; 24071 León, Spain
ROSA M. REGUERA
Affiliation:
Departamento de Farmacología y Toxicología (INTOXCAL), Universidad de León, Campus de Vegazana s/n; 24071 León, Spain
*
*Corresponding author: Departamento de Ciencias Biomédicas (INTOXCAL), Universidad de León, Campus de Vegazana s/n; 24071 León, Spain. Tel: +34 987 291257. Fax: +34 987 291252. E-mail: myperp@unileon.es
Rights & Permissions [Opens in a new window]

Summary

Methionine adenosyltransferase (MAT) is an important enzyme for metabolic processes, to the extent that its product, S-adenosylmethionine (AdoMet), plays a key role in trans-methylation, trans-sulphuration and polyamine synthesis. Previous studies have shown that a MAT-overexpressing strain of Leishmania donovani controls AdoMet production, keeping the intracellular AdoMet concentration at levels that are compatible with cell survival. This unexpected result, together with the fact that MAT activity and abundance changed with time in culture, suggests that different regulatory mechanisms acting beyond the post-transcriptional level are controlling this protein. In order to gain an insight into these mechanisms, several experiments were carried out to explain the MAT abundance during promastigote cell growth. Determination of MAT turnover in cycloheximide (CHX)-treated cultures resulted in a surprising 5-fold increase in MAT turnover compared to CHX-untreated cultures. This increase agrees with a stabilization of the MAT protein, whose integrity was maintained during culture. The presence of proteasome inhibitors, namely MG-132, MG-115, epoxomycin and lactacystin in the culture medium prevented MAT degradation in both MAT-overexpressing and ‘mock-transfected’ leishmanial strains. The role of the ubiquitin (Ub) pathway in MAT down-regulation was supported using immunoprecipitation experiments. Immunoprecipitated MAT cross-reacted with anti-Ub antibodies, which provides evidence of a proteasome-mediated down-regulation of the leishmanial MAT abundance.

Information

Type
Research Article
Copyright
Copyright © Cambridge University Press 2011
Figure 0

Fig. 1. Developmental expression of MAT along the growth curve of Leishmania donovani promastigotes. Culture was initiated at 1×106 promastigotes/ml and 24 h later, the culture at a density of 5×106 cells/ml was divided into two. One half was treated with 10 μg/ml CHX. The control culture grew normally, whereas the CHX-treated portion stopped its growth immediately. (A) Western analysis showing the MAT abundance of MAT-over-expressing L. donovani promastigotes after 24, 36, 48, 54 and 60 h. (B) Western analysis showing MAT protein abundance during the complete cell cycle (from 24 h to 60 h) of L. donovani promastigotes treated with 10 μg/ml CHX. Whole lysates harvested from L. donovani promastigotes (containing 15 μg of protein), were resolved by SDS-PAGE, blotted and incubated with a polyclonal-MAT antiserum. Loading controls made with a H2A antibody have been included below each blot. (C) MAT activity from L. donovani promastigotes, treated (○) or not (●) with 10 μg/ml CHX. Each spot represents the mean±s.d. of 3 representative experiments, using a paired t-test. ** P⩽0·001 regarding control; * P⩽0·01 regarding control cells.

Figure 1

Fig. 2. Effect of proteasome inhibitors on Leishmania donovani MAT stability. Cells were seeded at a density of 1 million/ml. After 24 h, the culture (at a density of 5×106 cells/ml) was divided and one half was treated with 5 μm MG 132. The control culture grew normally, whereas the MG 132-treated culture stopped its growth. (A) Western analysis measuring MAT protein abundance of L. donovani promastigotes (‘mock-transfected’ strain) after 24, 48, 60, 72, 84, 96 and 108 h, in the absence and presence of 5 μm MG 132. (B) Western analysis of MAT-over-expressing promastigotes after 24, 48, 60, 72, 84, 96 and 108 h in the absence and presence of 5 μm MG 132. (C) MAT activity present in the lysates from ‘mock-transfected’ and MAT-over-expressing promastigotes untreated (●) and treated (○) with 5 μm MG 132. The arrow represents the time-point for the addition of MG 132. (D) Western analysis of the lysates obtained from MAT-over-expressing promastigotes. Lane 1 represents the MAT-immunoreactive protein at time 0 (before the addition of the inhibitors), whereas lane 2 represents the same control (untreated cells) 48 h later. Lanes 3–6 correspond to leishmanial lysates treated for 48 h with 5 μm MG 132 (lane 3), 5 μm MG 115 (lane 4), 25 μm lactacystin (lane 5) and 2·5 μm epoxomycin (lane 6). Leishmanial histone 2A (H2A) was used as loading control.

Figure 2

Fig. 3. Pulse-chase experiments of MAT stability in Leishmania donovani promastigotes; (A) ‘mock-transfected’ and (B) MAT-over-expressing L. donovani promastigotes were pulse-labelled for 7 h with L-[35S]-cysteine/methionine Pro-Mix™ (Amersham®), and chased for 0, 12 and 24 h in serum-free medium in the absence (−) or presence (+) of 5 μm MG-132. The [35S]-labelled MAT was immunoprecipitated using anti-MAT antiserum and detected by autoradiography. The image shows a representative picture of 4 independent experiments.

Figure 3

Fig. 4. MAT is ubiquitinated in vivo. Immunoprecipitation assays of Leishmania donovani promastigotes with Ub-antiserum. Wild-type cultures were harvested and lysed, and the MAT protein was immunoprecipitated using a specific monoclonal Ub-antiserum. Western blot analysis of the immunoprecipitated protein incubated with anti-MAT polyclonal antiserum. Lane C: immunoprecipitation assay using lysis buffer as sample. Lane 1: MWM. Lane 2: MAT at time 0. Lanes 3–5: time-dependence trend of ubiquitination at 3, 6 and 12 h after subpassage. Lanes 6–8: MAT degradation is prevented with 5 μm MG-132 at the same harvesting times. The panel shows a representative picture of 3 independent experiments.

Figure 4

Fig. 5. Leishmanial MAT is phosphorylated in vitro, but its allosteric parameters are not modified. Three units of rat brain PKC were used to phosphorylate 5 μg of purified recombinant MAT from Leishmania donovani at different time-points. (A) Autoradiography of the SDS/PAGE showing in vitro MAT-phosphorylation. (B) MAT kinetics at variable concentrations of ATP and methionine saturation (left panel) and conversely, at variable methionine concentrations and ATP saturation (right panel) using a PKC-phosphorylated (○) and non-phosphorylated (●) recombinant MAT.

Figure 5

Fig. 6. MAT-over-expressing leishmanial promastigotes produce 2 isoforms of MAT with different phosphorylation patterns. Mock-transfected and MAT-over-expressing promastigotes were grown up to 24 h after subpassage. Cells were harvested and soluble extracts were obtained and analysed by 2-DE. The picture shows the enlarged region of 1 representative gel, which includes the MAT protein. The gel performed with MAT-over-expressing promastigotes shows 2 intense spots (1A and 1B indicated with arrows) clearly not visible in the mock-transfected cells. These spots were digested with trypsin and identified by MS/MS spectrometry, corresponding to the MAT protein. Some of the peptides contained phosphorylated amino acids (see embedded Table 1).